Long-term Follow-up Study of BHC001 in the Treatment of Transfusion-dependent β-thalassemia
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY
Observe long-term safety risk and long-term efficacy after intravenous infusion of BHC001 in TDT subjects.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 5
Maximum Age: 35
Healthy Volunteers: f
View:
• Provision of written informed consent for this study by subjects, or as applicable, subject's parent(s)/legal guardian(s)
• Treated with BRL-101 for therapy of transfusion-dependent β-thalassemia.
Locations
Other Locations
China
Xiangya Hospital of Central South University
RECRUITING
Changsha
The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army
RECRUITING
Nanning
Contact Information
Primary
Xiaochen Wang, PhD
xcwang@brlmed.com
021-64340008
Time Frame
Start Date: 2022-12-14
Estimated Completion Date: 2037-05-10
Participants
Target number of participants: 6
Treatments
BRL-101
All patients who have received BRL-101
Related Therapeutic Areas
Sponsors
Collaborators: The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army, Xiangya Hospital of Central South University
Leads: Bioray Laboratories